Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia

Kazunari Aoki, Mizuki Hyuga, Yusuke Tarumoto, Gohei Nishibuchi, Atsushi Ueda, Yotaro Ochi, Seiichi Sugino, Takashi Mikami, Hirokazu Kobushi, Itaru Kato, Koshi Akahane, Takeshi Inukai, Akifumi Takaori-Kondo, Junko Takita, Seishi Ogawa, Kosuke Yusa

Blood (2024) 143 (7): 604–618.

https://doi.org/10.1182/blood.2023020857

Published: 2024

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Hiroshi Imanaga, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koshi Akahane, Takeshi Inukai, Koichi Akashi, Takahiro Maeda

Blood (2023) 142 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2023-182620

Published: 2023

Journal Articles

The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia

Yunchao Chang, Fatemeh Keramatnia, Pankaj S. Ghate, Gisele Nishiguchi, Qingsong Gao, Ilaria Iacobucci, Lei Yang, Divyabharathi Chepyala, Ashutosh Mishra, Anthony A. High, Hiroaki Goto, Koshi Akahane, Junmin Peng, Jun J. Yang, Marcus Fischer, Zoran Rankovic, Charles G. Mullighan

Blood (2023) 142 (7): 629–642.

https://doi.org/10.1182/blood.2022017813

Published: 2023

Includes: Supplemental data

Journal Articles

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2022) 139 (5): 748–760.

https://doi.org/10.1182/blood.2021012976

Published: 2022

Includes: Supplemental data

Journal Articles

Degradation of Janus kinases in CRLF2 -rearranged acute lymphoblastic leukemia

Blood (2021) 138 (23): 2313–2326.

https://doi.org/10.1182/blood.2020006846

Published: 2021

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda

Blood (2021) 138 (Supplement 1): 2257.

https://doi.org/10.1182/blood-2021-152027

Published: 2021

Journal Articles

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Yaqi Zhao, Ibrahim Aldoss, Chunxu Qu, Jeremy Chase Crawford, Zhaohui Gu, Emma K. Allen, Anthony E. Zamora, Thomas B. Alexander, Jeremy Wang, Hiroaki Goto, Toshihiko Imamura, Koshi Akahane, Guido Marcucci, Anthony S. Stein, Ravi Bhatia, Paul G. Thomas, Stephen J. Forman, Charles G. Mullighan, Kathryn G. Roberts

Blood (2021) 137 (4): 471–484.

https://doi.org/10.1182/blood.2020006287

Published: 2021

Includes: Supplemental data

Journal Articles

Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL

Blood (2020) 136 (20): 2319–2333.

https://doi.org/10.1182/blood.2019004090

Published: 2020

Includes: Supplemental data

Journal Articles

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Yoichi Tanaka, PhD, Kevin Y Urayama, PhD MPH, Makiko Mori, MD, Daisuke Hasegawa, MD PhD, Yasushi Noguchi, MD, Masakatsu Yanagimachi, MD PhD, Dai Keino, MD PhD, Setsuo Ota, MD PhD, Koshi Akahane, MD PhD, Mayumi Hangai, MD, Takahisa Kawaguchi, Masatoshi Takagi, MD PhD, Katsuyoshi Koh, MD, Fumihiko Matsuda, Atsushi Manabe, MD PhD

Blood (2019) 134 (Supplement_1): 1347.

https://doi.org/10.1182/blood-2019-129440

Published: 2019

Journal Articles

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Koshi Akahane, MD PhD, Zhaodong Li, PhD, Julia Etchin, PhD, Alla Berezovskaya, Evisa Gjini, PhD, Craig E Masse, PhD, Wenyan Miao, PhD, Jennifer Rocnik, PhD, Rosana Kapeller, MD PhD, Jeremy R Greenwood, PhD, Hong Tiv, Takaomi Sanda, MD PhD, David M Weinstock, MD, A. Thomas Look, MD

Blood (2016) 128 (22): 1596.

https://doi.org/10.1182/blood.V128.22.1596.1596

Published: 2016

Journal Articles

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Meixian Huang, MD, Takeshi Inukai, MD, PhD, Keiko Kagami, BD, Masako Abe, BD, Tamao Shinohara, MD, Atsushi Watanabe, MD PhD, Koshi Akahane, MD PhD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Kumiko Goi, MD PhD, Yasuhiro Maeda, MD PhD, Seiichi Okabe, MD PhD, Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 1059.

https://doi.org/10.1182/blood.V128.22.1059.1059

Published: 2016

Journal Articles

Involvement of Allele-Specific Methylation of Asparagine Synthetase Gene in Asparaginase Sensitivity of BCP-ALL

Atsushi Watanabe, MD PhD, Takeshi Inukai, MD, PhD, Minori Tamai, MD PhD, Tamao Shinohara, MD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Koshi Akahane, MD PhD, Kumiko Goi, MD,PhD, Kunio Miyake, PhD, Kevin Urayama, PhD MPH, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 3966.

https://doi.org/10.1182/blood.V128.22.3966.3966

Published: 2016

Journal Articles

HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase

Koshi Akahane, Takaomi Sanda, PhD, Marc R. Mansour, MD PhD FRCPath, Julia Etchin, PhD, Ng Cherry, David M. Weinstock, MD, Anthony Letai, MD, PhD, Daniel J. DeAngelo, MD, Ph.D, A. Thomas Look, MD

Blood (2013) 122 (21): 2528.

https://doi.org/10.1182/blood.V122.21.2528.2528

Published: 2013

Journal Articles

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

Itaru Kuroda, MD, PhD, Takeshi Inukai, MD, PhD, Xiaochun Zhang, MD, PhD, Jiro Kikuchi, Yusuke Furukawa, Atsushi Nemoto, MD, PhD, Koshi Akahane, MD, PhD, Kinuko Hirose, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Hideo Yagita, PhD, Tetsuzo Tauchi, M.D., Yasuhiro Maeda, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 2740.

https://doi.org/10.1182/blood.V118.21.2740.2740

Published: 2011

Journal Articles

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Atsushi Nemoto, MD, PhD, Takeshi Inukai, MD, PhD, Koshi Akahane, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Yasuhiro Maeda, MD, PhD, Tetsuzo Tauchi, M.D., Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 1511.

https://doi.org/10.1182/blood.V118.21.1511.1511

Published: 2011

Journal Articles

Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)

Blood (2010) 116 (6): 962–970.

https://doi.org/10.1182/blood-2009-09-244673

Published: 2010

Includes: Supplemental data

Journal Articles

Induction of Death Receptors for TRAIL, a Cytotoxic Factor for GVL Effect, by Oncogenic Fusion E2A-HLF Derived from t(17;19)-Positive Acute Lymphoblastic Leukemia.

Xiaochun Zhang, Takeshi Inukai, Koshi Akahane, Kinuko Hirose, Itaru Kuroda, Hiroko Honna, Kumiko Goi, Keiko Kagami, Toshiya Inaba, Hidemitsu Kurosawa, Hiroaki Goto, Mikiya Endo, Hideo Yagita, A. Thomas Look, Kanji Sugita

Blood (2007) 110 (11): 2785.

https://doi.org/10.1182/blood.V110.11.2785.2785

Published: 2007

Journal Articles

E2A-HLF Fusion Transcription Factor Mediating Aberrant Expression of LMO2 in B-Precursor ALL with t(17;19).

Kinuko Hirose, Takeshi Inukai, Koshi Akahane, Xiaochun Zhang, Itaru Kuroda, Hiroko Honna, Kumiko Goi, Toshiya Inaba, A. Thomas Look, Shinpei Nakazawa, Kanji Sugita

Blood (2006) 108 (11): 1832.

https://doi.org/10.1182/blood.V108.11.1832.1832

Published: 2006

Journal Articles

Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).

Koshi Akahane, MD, Takeshi Inukai, MD, Toshiya Inaba, MD, Hidemitsu Kurosawa, MD, Mikiya Endo, MD, Hiroaki Goto, MD, Nobutaka Kiyokawa, MD, A. Thomas Look, MD, Kumiko Goi, MD, Kanji Sugita, MD, Shinpei Nakazawa, MD

Blood (2005) 106 (11): 851.

https://doi.org/10.1182/blood.V106.11.851.851

Published: 2005

NARROW

Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Degradation of Janus kinases in CRLF2 -rearranged acute lymphoblastic leukemia

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Involvement of Allele-Specific Methylation of Asparagine Synthetase Gene in Asparaginase Sensitivity of BCP-ALL

HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)

Induction of Death Receptors for TRAIL, a Cytotoxic Factor for GVL Effect, by Oncogenic Fusion E2A-HLF Derived from t(17;19)-Positive Acute Lymphoblastic Leukemia.

E2A-HLF Fusion Transcription Factor Mediating Aberrant Expression of LMO2 in B-Precursor ALL with t(17;19).

Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only